The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

Tenofovir was approved by the Food and Drug Administration (FDA) in October 2001 through an accelerated approval process; it is the first nucleotide analogue reverse-transcriptase inhibitor marketed ...

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...

One of the hallmarks of many DNA polymerases is that they proofread as they copy DNA, ensuring high-fidelity duplicates of an organism’s genome. This error-checking ability is missing from enzymes ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Antiretroviral drugs help prevent HIV from replicating in the body.

Key PointsResearch on HIV's conical capsid that began over 25 years ago led to the development of lenacapavir, the world's ...

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: HIV is neither the cause nor the sole cause of AIDS. This nonsense has been ...